Damora Therapeutics, Inc. (DMRA)

Market Cap	1.46B +38,558.3%
Revenue (ttm)	n/a
Net Income	-209.84M
EPS	-153.95
Shares Out	60.30M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	171,305
Open	25.01
Previous Close	24.99
Day's Range	23.96 - 25.30
52-Week Range	2.45 - 38.33
Beta	1.51
Analysts	Buy
Price Target	43.00 (+77.98%)
Earnings Date	May 22, 2026

About DMRA

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatmen...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 29, 2020
• Employees: 7
• Stock Exchange: NASDAQ
• Ticker Symbol: DMRA
• Website: https://www.damoratx.com

Analyst Summary

According to 2 analysts, the average rating for DMRA stock is "Buy." The 12-month stock price target is $43.0, which is an increase of 77.98% from the latest price.

Price Target

$43.0

(77.98% upside)

Analyst Consensus: Buy